• +1-646-491-9876
    • +91-20-67278686

    Search

    Ocular Hypertension - Pipeline Review, H1 2017

    Ocular Hypertension - Pipeline Review, H1 2017

    • Report Code ID: RW0001709483
    • Category Pharmaceuticals
    • No. of Pages 118
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Ocular Hypertension - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

    Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 8, 15, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

    Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology) .
    - The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Ocular Hypertension - Overview
    Ocular Hypertension - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Ocular Hypertension - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Ocular Hypertension - Companies Involved in Therapeutics Development
    Aerie Pharmaceuticals Inc
    Allergan Plc
    Bausch & Lomb Inc
    Can-Fite BioPharma Ltd
    D. Western Therapeutics Institute Inc
    F. Hoffmann-La Roche Ltd
    Inotek Pharmaceuticals Corp
    Ironwood Pharmaceuticals Inc
    Laboratoires Thea SA
    Laboratorios Sophia SA de CV
    Lee's Pharmaceutical Holdings Ltd
    Lexicon Pharmaceuticals Inc
    Neurim Pharmaceuticals Ltd
    NicOx SA
    Ocular Therapeutix Inc
    Santen Pharmaceutical Co Ltd
    Senju Pharmaceutical Co Ltd
    Sylentis SAU
    ViSci Ltd
    Ocular Hypertension - Drug Profiles
    (bimatoprost + timolol maleate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (latanoprost + netarsudil mesylate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (latanoprost + timolol maleate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (latanoprost + trabodenoson) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bamosiran - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bimatoprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bimatoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    H-1129 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IWP-953 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprostene bunod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    levobetaxolol hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LX-7101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MGV-354 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NCX-1653 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NCX-470 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NCX-667 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    netarsudil mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omidenepag isopropyl - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    piclidenoson - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    piromelatine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRO-067 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RO-5093151 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sepetaprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SNJ-1656 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trabodenoson - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    travoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    travoprost XR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Ocular Hypertension - Dormant Projects
    Ocular Hypertension - Discontinued Products
    Ocular Hypertension - Product Development Milestones
    Featured News & Press Releases
    Feb 27, 2017: Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod
    Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017
    Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering
    Jan 03, 2017: Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma
    Dec 23, 2016: Aerie Pharmaceuticals Provides Update on Timing of NDA Filing for Rhopressa (netarsudil ophthalmic solution) 0.02%
    Dec 07, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
    Oct 27, 2016: Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%
    Oct 04, 2016: Ocular Therapeutix Begins Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension
    Sep 06, 2016: Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02%
    Jul 22, 2016: Valeant Pharmaceuticals Receives Complete Response Letter From The FDA
    Jul 06, 2016: Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
    Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%
    May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
    Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension
    Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Ocular Hypertension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Ocular Hypertension - Pipeline by Aerie Pharmaceuticals Inc, H1 2017
    Ocular Hypertension - Pipeline by Allergan Plc, H1 2017
    Ocular Hypertension - Pipeline by Bausch & Lomb Inc, H1 2017
    Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd, H1 2017
    Ocular Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H1 2017
    Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corp, H1 2017
    Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
    Ocular Hypertension - Pipeline by Laboratoires Thea SA, H1 2017
    Ocular Hypertension - Pipeline by Laboratorios Sophia SA de CV, H1 2017
    Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
    Ocular Hypertension - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
    Ocular Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
    Ocular Hypertension - Pipeline by NicOx SA, H1 2017
    Ocular Hypertension - Pipeline by Ocular Therapeutix Inc, H1 2017
    Ocular Hypertension - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
    Ocular Hypertension - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
    Ocular Hypertension - Pipeline by Sylentis SAU, H1 2017
    Ocular Hypertension - Pipeline by ViSci Ltd, H1 2017
    Ocular Hypertension - Dormant Projects, H1 2017
    Ocular Hypertension - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Ocular Hypertension - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Ocular Hypertension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aerie Pharmaceuticals Inc
    Allergan Plc
    Bausch & Lomb Inc
    Can-Fite BioPharma Ltd
    D. Western Therapeutics Institute Inc
    F. Hoffmann-La Roche Ltd
    Inotek Pharmaceuticals Corp
    Ironwood Pharmaceuticals Inc
    Laboratoires Thea SA
    Laboratorios Sophia SA de CV
    Lee's Pharmaceutical Holdings Ltd
    Lexicon Pharmaceuticals Inc
    Neurim Pharmaceuticals Ltd
    NicOx SA
    Ocular Therapeutix Inc
    Santen Pharmaceutical Co Ltd
    Senju Pharmaceutical Co Ltd
    Sylentis SAU
    ViSci Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//ocular-hypertension-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//ocular-hypertension-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//ocular-hypertension-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments